Adam Laponis submitted a Form 144 notice reporting proposed sales of Common shares of TWST. The filing lists multiple sales in the past three months: 2,085 shares ($97,389.93), 2,597 shares ($129,561.48), 3,000 shares ($165,000.00), and 4,000 shares ($240,000.00). The filing also notes a restricted stock vesting event dated 05/20/2026.
Twist Bioscience Corp filed a Form 144 notice to sell 6,888 shares of Common Stock related to restricted stock vesting on 05/20/2026. The filing also lists multiple secondary transactions by Emily M. Leproust within the prior three months, including sales of 7,205 shares on 02/23/2026 and 8,061 shares on 04/22/2026.
The filing is a routine insider notice of proposed resale under securities rules and records recent dispositions by a reporting person; it does not state proceeds recipients beyond the selling person or additional conditions.
Dennis H. Cho reported a proposed resale of 1,642 shares of Common Stock on Form 144. The filing lists prior dispositions in the past three months: 844 shares on 02/23/2026 ($39,423.07), 425 shares on 03/06/2026 ($19,731.14), 354 shares on 03/20/2026 ($15,500.39), and 1,962 shares on 05/04/2026 ($112,125.95).
Twist Bioscience insider files a proposed sale of common stock. The filing lists 688 shares proposed for sale with Fidelity Brokerage Services LLC as broker and an execution date noted as 05/21/2026. The filing also discloses four prior open-market dispositions by Robert F. Werner totaling 6,064 shares across 02/23/2026, 03/06/2026, 05/04/2026, and 05/08/2026.
TWST filing: proposed resale of Common Stock following restricted stock vesting. The filing lists 4,160 shares of Common Stock to be sold in connection with a Restricted Stock Vesting event dated 05/20/2026. The filing also reports recent sales by Patrick Finn of 4,294, 2,321 and 2,844 shares on 02/23/2026, 04/23/2026 and 05/04/2026, respectively.
Twist Bioscience Corp director Jan Johannessen reported an option exercise and related share sale. Johannessen exercised employee stock options for 12,000 shares of common stock at $14.00 per share, increasing his holdings to 29,754 shares. On the same day, he completed an open-market sale of 12,000 common shares at an average price of $56.12 per share, leaving him with 17,754 shares held directly after the transactions. The options exercised had vested in stages over several years, subject to his continuous service.
Twist Bioscience Corp Chief Accounting Officer Robert F. Werner reported an open-market sale of Common Stock. He sold 4,961 shares on May 8, 2026 at a price of $56.881 per share. After this transaction, he directly holds 49,674 shares of Twist Bioscience Common Stock.
TWST affiliate reported resale notices under Form 144 for small, recent dispositions. The filing lists three resale transactions by Robert F. Werner: 1,693 shares for $79,079.70 on 02/23/2026, 246 shares for $11,420.85 on 03/06/2026, and 164 shares for $9,372.40 on 05/04/2026. The filing also lists multiple scheduled Restricted Stock Vesting items with dates and share counts (examples include 1,062 shares vesting 08/22/2024 and 977 shares vesting 02/22/2026).
Twist Bioscience Corp ownership update: William Blair Investment Management, LLC filed Amendment No. 2 to a Schedule 13G/A reporting beneficial ownership of 5,269,718 shares of Common Stock, representing 8.6% of the class. The filer reports sole voting power over 4,836,983 shares and sole dispositive power over 5,269,718 shares. The filing is signed by the Chief Compliance Officer on 05/07/2026.